JB Chemicals reports muted Q4 FY26 as integration resets business
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Subscribe To Our Newsletter & Stay Updated